Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2014
Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.
Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 61 citations in OpenAlex.
- Pharmacotherapy of Kienböck Disease and the Carpal Avascular Necrosis Family: A Narrative Review with a Four-Axis Translation Framework.Medicines (Basel, Switzerland) · 2026Review
- No Significant Differences between Bisphosphonates and Placebo for the Treatment of Bone Marrow Lesions of the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2024Review
- Osteonecrosis of the Knee: The Unintended Consequence of Steroid Abuse.Clinical medicine & research · 2024Article
- A Current Review in the Orthopedic Management of Osteonecrosis of the knee Secondary to Treatment of Pediatric Hematologic Malignancy.Orthopedic reviews · 2024Article
- Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions.Journal of functional biomaterials · 2023Article
- [Drug treatment of osteonecrosis].Orthopadie (Heidelberg, Germany) · 2022Review
- A Case of Subchondral Insufficiency Fracture of the Knee at Lateral Femoral Condyle Treated With Unicompartmental Knee Arthroplasty.Arthroplasty today · 2022Article
- Subchondral insufficiency fracture of the knee: review of current concepts and radiological differential diagnoses.Japanese journal of radiology · 2022Review
- Treatment options for secondary osteonecrosis of the knee.Orthopedic reviews · 2022Article
- Perspective on subchondral insufficiency fracture of the knee.Osteoarthritis and cartilage open · 2021Article
- Effect of Zoledronic Acid and Alendronate on Bone Edema and Pain in Spontaneous Osteonecrosis of the Knee: A New Paradigm in the Medical Management.Revista brasileira de ortopedia · 2020Article
- Alternate treatment approach to subchondral insufficiency fracture of the knee utilizing genicular nerve cooled radiofrequency ablation and adjunctive bisphosphonate supplementation: A case report.Radiology case reports · 2020Article
- Spontaneous osteonecrosis of the knee: what do we know so far? A literature review.International orthopaedics · 2020Review
- Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2020Article
- Treatment of spontaneous osteonecrosis of the knee by daily teriparatide: A report of 3 cases.Medicine · 2020Article
- Characteristics, management, and outcomes of spontaneous osteonecrosis of the knee in Indian population.International orthopaedics · 2018Article
- Review
- Subchondral Insufficiency Fracture in the Lateral Compartment of the Knee in a 64-Year-Old Marathon Runner.Knee surgery & related research · 2017Article
- Bone Marrow Lesion: Image, Clinical Presentation, and Treatment.Magnetic resonance insights · 2017Review
- Bone marrow lesions and subchondral bone pathology of the knee.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledBased on this double-blind, placebo-controlled study, ibandronate has no beneficial effect on clinical and radiological outcome in patients with spontaneous osteonecrosis of the knee over and above anti-inflammatory medication.
introductionObservational studies suggest beneficial effects of bisphosphonates in spontaneous osteonecrosis (ON) of the knee. We investigated whether ibandronate would improve clinical and radiological outcome in newly diagnosed ON.
methodsIn this randomized, double-blind, placebo-controlled trial, 30 patients (mean age, 57.3 ± 10.7 years) with ON of the knee were assigned to receive either ibandronate (cumulative dose, 13.5 mg) or placebo intravenously (divided into five doses 12 weeks). All subjects received additional treatment with oral diclofenac (70 mg) and supplementation with calcium carbonate (500 mg) and vitamin D (400 IU) to be taken daily for 12 weeks. Patients were followed for 48 weeks. The primary outcome was the change in pain score after 12 weeks. Secondary endpoints included changes in pain score, mobility, and radiological outcome (MRI) after 48 weeks.
resultsAt baseline, both treatment groups (IBN, n = 14; placebo, n = 16) were comparable in relation to pain score and radiological grading (bone marrow edema, ON). After 12 weeks, mean pain score was reduced in both ibandronate- (mean change, -2.98; 95% CI, -4.34 to -1.62) and placebo- (-3.59; 95% CI, -5.07 to -2.12) treated subjects (between-group comparison adjusted for age, sex, and osteonecrosis type, p = ns). Except for significant decrease in bone resorption marker (CTX) in ibandronate-treated subjects (p < 0.01), adjusted mean changes in all functional and radiological outcome measures were comparable between treatment groups after 24 and 48 weeks.
conclusionsIn patients with spontaneous osteonecrosis of the knee, bisphosphonate treatment (i.e., IV ibandronate) has no beneficial effect over and above anti-inflammatory medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.